Erythropoietin: The Kidney's Red Blood Cell Peptide

Vasopressin and Kidney Peptides

165 amino acids in the mature EPO protein

Erythropoietin is a 165-amino-acid glycoprotein hormone produced primarily by the kidneys in response to low oxygen. It drives red blood cell production in the bone marrow and has generated over $10 billion annually in pharmaceutical sales.

Jelkmann, Experimental Hematology, 2007

Jelkmann, Experimental Hematology, 2007

View as image

When oxygen levels drop, the kidneys respond by producing a single hormone that tells the bone marrow to make more red blood cells. That hormone is erythropoietin (EPO), a 165-amino-acid glycoprotein that has become one of the most commercially successful peptide-derived drugs in pharmaceutical history, one of the most infamous substances in sports doping, and a molecule with emerging therapeutic applications far beyond blood cell production.

EPO was among the first human hormones to be cloned and produced through recombinant DNA technology. Its approval in 1989 transformed the treatment of anemia in chronic kidney disease (CKD), where damaged kidneys cannot produce adequate EPO. Before recombinant EPO, CKD patients depended on blood transfusions that carried infection risks and iron overload. After approval, millions of dialysis patients received regular EPO injections to maintain hemoglobin levels.

For the broader context of how kidneys regulate fluid balance through peptide signaling, the pillar article on vasopressin and water reabsorption covers the parallel story of antidiuretic hormone. For the kidney's role in peptide-based blood pressure regulation, see the sibling article on the renin-angiotensin system.

How EPO Production Works: The Oxygen Sensing Pathway

EPO production is controlled by one of the most elegant sensing mechanisms in human physiology. The 2019 Nobel Prize in Physiology or Medicine was awarded to William Kaelin, Peter Ratcliffe, and Gregg Semenza for discovering this system: the HIF (hypoxia-inducible factor) pathway.

Under normal oxygen conditions, HIF-alpha subunits are continuously produced but immediately tagged for destruction. An enzyme called prolyl hydroxylase (PHD) adds hydroxyl groups to HIF-alpha, which allows the von Hippel-Lindau (VHL) protein to mark it for proteasomal degradation. The result: HIF-alpha is present but destroyed before it can activate gene transcription.

When oxygen drops, PHD cannot function (it requires molecular oxygen as a substrate). HIF-alpha accumulates, enters the nucleus, binds HIF-beta, and activates the EPO gene along with hundreds of other hypoxia-responsive genes. In the kidney, peritubular interstitial fibroblast-like cells in the deep cortex are the primary EPO-producing cells. These cells sit adjacent to peritubular capillaries and the proximal convoluted tubule, positioning them to sense local oxygen tension directly.

The liver also produces EPO (approximately 10-15% of total production in adults), a remnant of fetal physiology when the liver was the primary production site before birth. In severe anemia or chronic hypoxia, hepatic EPO production can increase, but it cannot compensate for the loss of renal production in advanced kidney disease.

EPO's Mechanism of Action

Circulating EPO binds the erythropoietin receptor (EpoR) on erythroid progenitor cells in the bone marrow. EpoR is a single-pass transmembrane protein that signals through the JAK2/STAT5 pathway. Binding activates JAK2 kinase, which phosphorylates STAT5 transcription factors. These enter the nucleus and activate genes that promote survival, proliferation, and differentiation of erythroid precursors into mature red blood cells.

The process takes approximately 5-7 days from EPO stimulation to the release of new reticulocytes (immature red blood cells) into the bloodstream. This delay is clinically relevant: patients starting EPO therapy do not see hemoglobin increases for 1-2 weeks, and full response takes 4-8 weeks.

EPO also signals through the PI3K/Akt and Ras/MAPK pathways, which contribute to cell survival (anti-apoptotic effects) and differentiation. The anti-apoptotic function is particularly important: EPO does not create new progenitor cells but rescues existing progenitors that would otherwise undergo programmed cell death. Without EPO signaling, approximately 90% of late-stage erythroid progenitors die. With EPO, this death rate drops to less than 10%, dramatically increasing red blood cell output from the same progenitor pool.

Clinical Therapeutics: Three Generations of EPO Drugs

First Generation: Recombinant EPO

Epoetin alfa (Epogen/Procrit) was approved by the FDA in 1989 for anemia of chronic kidney disease. It is produced in Chinese hamster ovary (CHO) cells and is structurally identical to endogenous human EPO. The drug requires subcutaneous or intravenous injection 1-3 times per week.

The clinical impact was transformative. Before recombinant EPO, CKD patients on dialysis maintained hematocrit levels of 20-25% (normal: 36-44%) through regular blood transfusions. EPO therapy raised hematocrit to 30-36%, reducing transfusion dependence, improving exercise capacity, and enhancing quality of life.

However, clinical trials in the 2000s revealed that targeting higher hemoglobin levels (above 13 g/dL) with aggressive EPO dosing increased the risk of cardiovascular events, stroke, and death. The CHOIR (2006) and CREATE (2006) trials, followed by TREAT (2009) in diabetic CKD patients, led to FDA black box warnings and a target hemoglobin range of 10-12 g/dL. This safety signal reshaped prescribing patterns and reduced EPO usage by approximately 20% in the years following the label changes.

Second Generation: Longer-Acting ESAs

Darbepoetin alfa (Aranesp) is a hyperglycosylated analog of EPO with two additional N-linked carbohydrate chains. The extra glycosylation extends the serum half-life from approximately 8 hours (epoetin alfa) to 25 hours, allowing dosing every 1-2 weeks instead of 1-3 times weekly. The structural modification demonstrates a peptide engineering principle: adding carbohydrate moieties slows renal clearance without altering receptor binding.

Methoxy polyethylene glycol-epoetin beta (Mircera) uses PEGylation to achieve an even longer half-life (approximately 130 hours), enabling once-monthly dosing. This is the same PEGylation strategy used across peptide therapeutics to extend circulation time.

Third Generation: HIF-PH Inhibitors

HIF-prolyl hydroxylase (HIF-PH) inhibitors represent a paradigm shift: instead of injecting recombinant EPO, these oral small molecules prevent the degradation of endogenous HIF-alpha, stimulating the patient's own kidneys and liver to produce more EPO.

Hida et al. (2024) reviewed the clinical implications of HIF-PH inhibitors in patients with combined heart failure, chronic kidney disease, and renal anemia. These patients represent the most challenging population for EPO therapy because they are sensitive to volume overload and cardiovascular risk from aggressive hemoglobin correction. HIF-PH inhibitors offered a more physiological approach: they increased EPO levels modestly (2-5 fold, versus the 100-1000 fold peaks from injected recombinant EPO), improved iron metabolism, and reduced hepcidin levels, addressing the functional iron deficiency that commonly limits EPO responsiveness in CKD.^[1]

Yoshitake et al. (2025) examined how HIF-PH inhibitors affect the relationship between B-type natriuretic peptide (BNP, a cardiac stress marker) and hemoglobin levels in CKD patients. The study provided evidence that HIF-PH inhibitors improve anemia without the cardiac stress signals associated with high-dose injected ESAs, suggesting a better safety profile for patients with concurrent heart disease.^[2]

Roxadustat was the first HIF-PH inhibitor approved (China, 2018; EU, 2021). Daprodustat received FDA approval in 2023. Vadadustat and molidustat are approved in select markets. These drugs are taken orally, typically three times weekly, and have the potential to replace injected ESAs for many CKD patients.

EPO-Mimetic Peptides: Simplifying the Molecule

Rather than producing the full 165-amino-acid glycoprotein through cell culture, researchers have developed synthetic peptides that activate the EPO receptor with much smaller molecules.

Liu et al. (2025) characterized pegmolesatide, a novel synthetic EPO-mimetic agent, for anti-doping analysis. Pegmolesatide is a PEGylated peptide with no structural homology to EPO itself but binds and activates the EPO receptor through a different binding site. It was approved in China in 2022 for CKD anemia and represents a new class of erythropoiesis-stimulating agents: synthetic peptide mimetics that are cheaper to manufacture than recombinant glycoproteins and potentially more consistent in quality.^[3]

The earlier EPO-mimetic peptide peginesatide (Omontys) was FDA-approved in 2012 but withdrawn from the US market in 2013 after reports of serious hypersensitivity reactions including anaphylaxis. The withdrawal illustrated the challenge of synthetic peptide mimetics: while they can activate the target receptor, their novel structures may trigger immune responses that the body's natural hormone does not.

The Doping Legacy

EPO's impact on sports, particularly endurance cycling, is among the most consequential doping stories in athletic history. Recombinant EPO became available to athletes in the late 1980s, before any detection method existed. By increasing red blood cell mass and oxygen-carrying capacity, EPO could improve endurance performance by 5-10%.

The substance defined professional cycling in the 1990s and 2000s. The USADA investigation that led to Lance Armstrong's lifetime ban in 2012 documented systematic EPO use across multiple Tour de France teams. The sport's governing body, the UCI, eventually introduced the Athlete Biological Passport (ABP) in 2008, which tracks longitudinal changes in blood parameters rather than testing for the drug directly.

Detection evolved through three phases. Direct detection uses isoelectric focusing (IEF) to distinguish recombinant EPO (produced in CHO cells with different glycosylation patterns) from endogenous EPO. Indirect detection monitors hemoglobin, reticulocyte percentage, and serum EPO levels through the ABP. Newer methods detect EPO biosimilars and next-generation ESAs like pegmolesatide.

For the full story of EPO in competitive sports, see EPO: the peptide that defined endurance doping. For how modern anti-doping laboratories detect peptide-based performance enhancers, see how peptide doping is detected and emerging peptide doping threats.

Beyond Erythropoiesis: Tissue-Protective Effects

EPO receptors are expressed outside the bone marrow, including in the brain, heart, and kidneys themselves. This has led to investigation of EPO's tissue-protective properties beyond red blood cell production.

In animal models of stroke and traumatic brain injury, EPO administration reduced infarct size and improved neurological outcomes. The mechanism appears to involve the anti-apoptotic JAK2/STAT5 pathway activated in neurons, similar to its erythroid survival signaling. However, clinical translation has been difficult. The AsTrAL trial (2017) found no benefit of EPO in acute ischemic stroke, and the EPO-TBI trial in traumatic brain injury showed no improvement in neurological outcomes.

Cardioprotective effects have been demonstrated in animal models of myocardial infarction, where EPO reduces cardiomyocyte apoptosis and infarct size. Clinical trials have produced mixed results, with some showing benefit in the acute setting and others finding no effect or increased adverse events.

The tissue-protective applications face a fundamental challenge: the doses required for neuroprotection or cardioprotection are often higher than those for erythropoiesis, increasing the risk of thromboembolic complications from excessive red blood cell production. Non-erythropoietic EPO derivatives (carbamylated EPO, ARA 290) have been developed to separate the tissue-protective from the erythropoietic effects, but none has reached clinical approval.

For the broader context of peptide therapies targeting kidney disease, see peptide therapeutics for chronic kidney disease and natriuretic peptides and sodium.

Limitations and Ongoing Challenges

Cardiovascular risk. Higher hemoglobin targets with ESA therapy increase stroke, myocardial infarction, and death risk. Current guidelines recommend conservative targets (10-12 g/dL). The mechanism may involve increased blood viscosity, hypertension from reduced nitric oxide bioavailability, or direct pro-thrombotic effects of high-dose ESA.

Pure red cell aplasia (PRCA). In rare cases, anti-EPO antibodies neutralize both the drug and the patient's endogenous EPO, causing severe transfusion-dependent anemia. This was most clearly linked to a specific epoetin alfa formulation (Eprex) when administered subcutaneously, linked to leachates from rubber stoppers in pre-filled syringes. Reformulation largely eliminated this risk, but it remains a theoretical concern with any EPO product.

ESA hyporesponsiveness. Approximately 10-20% of CKD patients respond poorly to ESA therapy, requiring higher doses to achieve target hemoglobin levels. Iron deficiency, chronic inflammation, hyperparathyroidism, and aluminum toxicity are common causes. Managing hyporesponsiveness requires identifying and treating the underlying condition rather than escalating ESA doses.

Cost and access. While biosimilar competition has reduced EPO prices (epoetin alfa biosimilars launched in Europe in 2007 and the US in 2018), the drug remains expensive in many markets. HIF-PH inhibitors may eventually reduce costs further by replacing injectable biologics with oral small molecules, but current pricing does not yet reflect this advantage.

The Bottom Line

Erythropoietin is a 165-amino-acid glycoprotein hormone produced by the kidneys in response to low oxygen, driving red blood cell production through the JAK2/STAT5 signaling pathway. Recombinant EPO, approved in 1989, transformed CKD anemia treatment but revealed cardiovascular risks at higher hemoglobin targets. Three generations of EPO drugs have evolved: recombinant EPO (1989), longer-acting glycoengineered variants (darbepoetin), and now oral HIF-PH inhibitors that stimulate endogenous EPO production. Synthetic EPO-mimetic peptides like pegmolesatide represent a fourth approach. EPO's doping legacy reshaped anti-doping enforcement in professional sports. Tissue-protective applications beyond erythropoiesis remain under investigation but have not achieved clinical success.

Frequently Asked Questions

What does erythropoietin do in the body?

Erythropoietin (EPO) is a hormone produced primarily by the kidneys that stimulates red blood cell production in the bone marrow. When blood oxygen levels drop, the kidneys detect the change through the HIF pathway and increase EPO secretion. EPO binds receptors on erythroid progenitor cells, activating survival signals that prevent programmed cell death and promoting differentiation into mature red blood cells.

Why do kidney disease patients need EPO injections?

Chronic kidney disease damages the cells that produce EPO, leading to a deficiency that causes anemia (low red blood cell count). Before recombinant EPO, CKD patients on dialysis had dangerously low hematocrit levels (20-25% versus normal 36-44%) and required regular blood transfusions. Injectable EPO replacement raises hemoglobin to target levels of 10-12 g/dL, reducing transfusion dependence and improving quality of life.

What are HIF-PH inhibitors and how do they replace EPO injections?

HIF-PH inhibitors are oral pills that block the enzyme (prolyl hydroxylase) that normally destroys HIF-alpha, the transcription factor controlling EPO production. By preventing HIF-alpha degradation, these drugs stimulate the patient's own kidneys and liver to produce more EPO naturally. Roxadustat, daprodustat, and vadadustat are approved in various markets. They produce more modest EPO elevations than injected recombinant EPO, with potentially better cardiovascular safety.

How is EPO doping detected in athletes?

Detection uses multiple methods. Direct testing distinguishes recombinant EPO from natural EPO by isoelectric focusing, exploiting glycosylation differences between CHO cell-produced and human-produced EPO. Indirect detection through the Athlete Biological Passport monitors longitudinal changes in hemoglobin and reticulocyte levels. Newer methods detect next-generation agents like synthetic EPO-mimetic peptides (pegmolesatide) that do not share EPO's structure.

Is EPO a peptide or a protein?

Mature EPO is a 165-amino-acid glycoprotein, placing it at the boundary between large peptides and small proteins. It is heavily glycosylated, with approximately 40% of its molecular weight coming from carbohydrate chains that are essential for its biological activity and half-life. In pharmaceutical classification, EPO is categorized as a biologic (a large-molecule protein drug produced in cell culture) rather than a peptide drug.

Does EPO have effects beyond making red blood cells?

EPO receptors are expressed in the brain, heart, and kidneys, where EPO activates anti-apoptotic (cell survival) pathways. Animal studies show neuroprotective effects in stroke and traumatic brain injury models, and cardioprotective effects in myocardial infarction models. Clinical trials have produced mixed results, and no tissue-protective EPO therapy is approved. The challenge is that doses needed for neuroprotection increase red blood cell production to potentially dangerous levels.